The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine activated killer cells induced in vitro

This publication has 17 references indexed in Scilit:

• In vivo augmentation of the cytotoxicity of spleen lymphocytes against syngeneic B-16 melanoma cells and the suppression of the artificial metastases in C57BL/6 mice by subcutaneous multiple injections of high dose human recombinant interleukin-2 (rIL-2)
  Zeitschrift für Krebsforschung und Klinische Onkologie, 1986
• Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer
  New England Journal of Medicine, 1985
• Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
  The Journal of Experimental Medicine, 1985
• Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2
  Science, 1984
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
  The Journal of Experimental Medicine, 1984
• IN VIVO ADMINISTRATION OF INTERLEUKIN-2 ENHANCES SPECIFIC ALLOIMMUNE RESPONSES
  Transplantation, 1983
• In vivo effect of anti-asialo GM1 antibody on natural killer activity
  Nature, 1981
• INVITRO GROWTH OF CYTO-TOXIC HUMAN-LYMPHOCYTES .4. LYSIS OF FRESH AND CULTURED AUTOLOGOUS TUMOR BY HUMAN-LYMPHOCYTES CULTURED IN T-CELL GROWTH-FACTOR
  1981
• A glycolipid on the surface of mouse natural killer cells
  European Journal of Immunology, 1980
• T Cell Growth Factor: Parameters of Production and a Quantitative Microassay for Activity
  The Journal of Immunology, 1978